申请人:Gambacorti Passerini Carlo
公开号:US20110281862A1
公开(公告)日:2011-11-17
The present invention relates to compounds of formula (I)
wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
本发明涉及式(I)的化合物,其中R1,R2和R3如描述中所定义,以及它们的制药组合物和用于治疗表达癌基因ALK蛋白的癌症的用途,特别是间变性大细胞淋巴瘤(ALCL),弥漫性大B细胞淋巴瘤(DLBCL),炎性肌成纤维细胞瘤(IMT)和非小细胞肺癌(NSCLC)。